Effet de l’implantation d’une clinique de prescription médicale d’héroïne sur l’environnement communautaire

Fischer B, Rehm J, Kirst M, Casas M, Hall W, Krausz M, et coll. Heroinassisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health 2002;12(3):228–34.

Fischer B, Cruz M F, Rehm J. Illicit opioid use and its key characteristics: A select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatry 2006;51(10):624–34.

National Institute on Drug Abuse. Heroin abuse and addiction. Res Report Series 2005;1–8.

Schneeberger P, Guèvrement PA. NAOMI–North American Opiate Medication Initiative, présenté dans le cadre de la Tournée des Partenaires du RISQ, avril 2007.

Dony EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 2005;100:1496–509.

Murray JB. Effectiveness of methadone maintenance for heroin addiction. Psychol Rep 1998;83:295–302.

Harris AH, Gospodarevskaya E, Ritter AJ. A randomized trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005;23(1):77–91.

Léonard L, Ben Amar M. Les psychotropes: pharmacologie et toxicomanie. Montréal, QC: Les presses de l’Université de Montréal, 2002).

Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. Int J Neuropsychopharmacology 2008;11(5):641–53.

Mattick RP, Kimber J. Buprenorphine maintenance versus placebo or metha-done maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2003;2:CD002207.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus metha-done in the treatment of opioid-dependent cocaine users. Psychopharmaco-logy 1994;116(4):401–6.

Dijkgraaf MGW, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. Br Med J 2005;330(7503):1297–303.

Satel SL, Aeschbach E. The Swiss heroin trials. J Subst Abuse Treatment 1999;17(4):331–35.

Verthein U, Bonorden-Kleij K, Degkwitz P, Dilg C, Köhler WK, Passie T, et coll. Long-term effects of heroin-assisted treatment in Germany. Addiction 2008;103(6):960–66.

Symonds A, Staunton PJ, Cohen I, Jobling J, Kerr M, Meagher R, et coll. Report on the Establishment or Trial of Safe Injecting Rooms 1998. Parliament of New South Wales, NSW, Australia, 1998:1–294.

Dehue T. A Dutch treat: Randomized controlled experimentation and the case of heroin-maintenance in the Netherlands. History Human Sci 2002;15(2):75–98.

Bennett RR, Flavin JM. Determinants of fear of crime: The effect of cultural setting. Justice Q 1994;11(3):357–81.

Skogan WG. Disorder and Decline: Crime and the Spiral of Decay in American Cities. New York, NY: University of California Press, 1990).

Pikora T, Giles-Corti B, Bull F, Jamrozik K, Donovan R. Developing a framework for assessment of the environmental determinants of walking and cycling. Soc Sci Med 2003;56(8):1693–703.

Goldstein PJ. The drugs/violence nexus. A tripartite conceptual framework. J Drug Issues 1985;14:493–506.

Goldstein JP. Drugs and violent crime. In: Weiner NA, Wolfgang ME (Éds.). Pathways to Criminal Violence. Newbury Park, CA: Sage, 1989).

Manzoni P, Brochu S, Fischer B, Rehm J. Determinants of property crime among illicit opiate users outside of treatment across Canada. Deviant Behavior 2006;27:351–76.

Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter M. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009;361:777–86.

Bear MF, Connors BW, Paradiso MA. Neurosciences: À la découverte du cerveau, 2e édition. Baltimore, MD: Lippincott Williams et Wilkins, 2002).

Lamoureux A. Recherche et méthodologie en sciences humaines, 3e édition. Laval, QC: Éditions Études Vivantes, 2000).

Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston, MA: Houghton Mifflin, 2002).

Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299–309.

Ouimet M, Fortin F. Les voies de fait au fil des jours. Dans: Cusson M, Ouimet M, Proulx J (Éds.). Les violences criminelles. Ste-Foy, QC: Les Presses de l’Université Laval, 1999).

Brisson P. L’approche de réduction des méfaits: sources, situation, pratiques. Comité permanent de lutte à la toxicomanie, Montréal, QC: Gouvernement du Québec, 1997):1–127.

Lasnier B, Brochu S, Boyd N, Fischer B. A heroin prescription trial: Case studies from Montreal and Vancouver on crime and disorder in the surrounding neighbourhoods. Int J Drug Pol 2010;21(1):28–35.